Pfizer Inc. (NYSE:PFE) has been upgrading its facility that produces injectable medicine. However, that upgrade has been long overdue and the facility has remained out of operation for five weeks longer than anticipated. So then, the company says that it expects shortage of the injectables manufactured at the plant. A similar shortage warning had initiated come from FDA. The company promises that the enjectables will be available starting the first week of March, but full production recover will not be realized until June. Pfizer Inc. (NYSE:PFE) traded on the positive path, adding 7 cents on each of its shares, thus ending the day at $31.55 per share. Pfizer Inc. (NYSE:PFE) stock opened at $31.55 in last session, and closed at $31.89, while the day range of PFE stock is $31.54-$31.99.The stock showed a positive weekly performance of 0.03%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO) is headed by an eminent pharmacology expert, Dr.J.Joshep Kim who holds the company and its inventions as personal achievements. In fact, Inovio Pharmaceuticals Inc (NYSEMKT:INO) has far long been the history of Kim himself as he has been Instrumental in beginning the institutions which has so many academic and clinical accolades to rest on. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock opened at $3.87, in last session and closed at $3.56, by loosed -4.30%.The 52 week range was $0.49-$3.95.Company’s market capitalization is $741.82 million.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) releases its fiscal 2013 fourth quarter early morning Tuesday, February 25. The company is expected to report earnings of (47 cents) per share. Revenue is expected to come in at $6.31 million. These are estimates issued by analysts tracking the stock. ARIA has a consensus “hold” rating and average price objective of $7.36 as result of 23 analysts tracking the ticker. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) lost 2.71 percent in the last session, leading the share to close at $8.63. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock gained 0.46% and finished the last session at $8.67.The EPS of the stock remained -1.46.Company’s market capitalization is $1.61 billion.
VIVUS, Inc. (NASDAQ:VVUS) beat its earnings estimates. Qsymia prescriptions grew about 14% sequentially. Still, this is only about 124,000 prescriptions so far. Net product sales of Qsymia were up about 20% to $7.7 million in the quarter, and this was supposedly harmed by the holiday season. VIVUS, Inc. (NASDAQ:VVUS) stock opened the session at $5.77, and closed the session at $5.86. The 52 week range of the VVUS stock remained $5.77-$15.62 and the day range was $5.77-$6.24.
Leave a Reply